GBT - GBT STOCK NEWS

Global Blood Therapeutics (GBT) recently announced the granting of 26,450 shares of restricted stock units to 14 new employees as of May 1, 2021. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan, in compliance with NASDAQ Listing Rule 5635(c)(4). The Plan aims to incentivize new hires, supporting GBT's mission to transform treatments for sickle cell disease (SCD). This initiative underscores the company’s commitment to employee growth and innovation in biopharmaceuticals.

Global Blood Therapeutics (GBT) has announced its participation in two upcoming investor conferences. The first is the Bank of America 2021 Healthcare Conference on May 12 at 4:15 p.m. ET, followed by the RBC Capital Markets Global Healthcare Conference on May 19 at 3:05 p.m. ET. Both events will be available via live webcast on GBT's website. Established in 2011, GBT focuses on developing treatments for sickle cell disease, most notably through its FDA-approved treatment, Oxbryta, and advanced pipeline projects.

GBT reported net revenues of $39.0 million for Oxbryta in Q1 2021, marking a 177% increase year-over-year. However, revenues fell 5% sequentially due to lower inventory and higher adjustments. The firm recorded approximately 950 new prescriptions amid the COVID-19 pandemic, and believes prescriptions will improve as conditions normalize. R&D expenses rose to $50.9 million while SG&A expenses increased to $59.0 million. GBT incurred a net loss of $74.9 million in Q1 with cash holdings of $482.0 million.

Global Blood Therapeutics (GBT) and the Sickle Cell Disease Association of America (SCDAA) have launched the "Lift Every Voice to Shine the Light on Sickle Cell" contest in observance of World Sickle Cell Day on June 19, 2021. The initiative invites individuals with sickle cell disease (SCD) to submit original spoken word pieces, helping to raise awareness of the disease. For every eligible entry, GBT will donate $100 to SCDAA, up to a maximum of $5,000. The winner will be recognized at the SCDAA Annual Convention in October 2021, with performances streamed online on June 18 and 19.

Global Blood Therapeutics (GBT) will release its Q1 2021 financial results on May 5, 2021, after market close. Management will host a conference call at 4:30 p.m. ET to discuss the results and provide a business update. GBT is focused on developing treatments for sickle cell disease (SCD), including Oxbryta, its FDA-approved therapy. The company is also advancing its pipeline with inclacumab and GBT021601. Investors can access the conference call via the company's website.

Global Blood Therapeutics (GBT) has released promising data from the Phase 3 HOPE Study of Oxbryta (voxelotor) for treating sickle cell disease (SCD). The study indicated significant improvements in hemoglobin levels and overall health in patients over 72 weeks. Approximately 90% of Oxbryta-treated patients demonstrated an increase in hemoglobin, with a notable reduction in acute anemic episodes. The drug is FDA-approved for patients aged 12 and older, and results pave the way for expanded approvals and potentially transformative outcomes for SCD patients.

Global Blood Therapeutics (GBT) announced the granting of 12 new employees restricted stock units totaling 47,750 shares on April 1, 2021. These awards were given under the Amended and Restated 2017 Inducement Equity Plan as an inducement for their employment, complying with NASDAQ Listing Rule 5635(c)(4). GBT focuses on developing treatments for sickle cell disease, having introduced the first FDA-approved treatment Oxbryta and advancing other pipeline programs including inclacumab and GBT021601.

Global Blood Therapeutics (GBT) announced the appointment of Alexis A. Thompson, M.D., M.P.H. to its board of directors, effective March 18, 2021. Dr. Thompson is a renowned hematologist specializing in sickle cell disease (SCD), with extensive experience in patient care and clinical research. Her role will significantly contribute to GBT's research and development efforts as the company aims to enhance care for patients with SCD. GBT is known for its commitment to addressing health disparities and advancing innovative therapies.

Global Blood Therapeutics (GBT) announced an exclusive licensing agreement with Sanofi for two early-stage research programs aimed at treating sickle cell disease (SCD). GBT will gain worldwide rights to programs that focus on novel anti-sickling mechanisms and inflammation reduction. The deal includes an upfront payment and potential milestones totaling approximately $353 million. This collaboration enhances GBT’s pipeline and supports its goal to transform SCD treatment through patient-friendly oral therapies.